Aripiprazole versus Brexpiprazole for People with Schizophrenia: A Systematic Review
##plugins.themes.bootstrap3.article.main##
Abstract
Introduction: Schizophrenia is a chronic, complex, and multifactorial psychiatric disorder characterized by various clinical manifestations. The first line of treatment for this condition is antipsychotics. Second-generation antipsychotics use partial agonist mechanisms of D2 receptors that regulate dopaminergic tone, presumably reducing the incidence of extrapyramidal symptoms. Two second-generation molecules that have shown adequate efficacy for the treatment of positive symptoms in schizophrenia are aripiprazole and brexpiprazole and there are reviews comparing their effectiveness and safety in treatments of up to four weeks.
Objective: To evaluate the efficacy and tolerability of aripiprazole compared with brexpiprazole in people diagnosed with schizophrenia or schizophrenia-like psychosis in medium- and long-term treatments.
Method: The search was conducted by a specialist from the Cochrane schizophrenia group on March 9, 2023, in the MEERKAT registry, for (*Aripiprazole* and *Brexpiprazole*).
Results: A total of 166 registers were identified from the electronic searches. Fifteen were eliminated due to duplication. The titles and abstracts of 151 records were examined, and four full texts were retrieved and assessed for eligibility according to inclusion and exclusion criteria. During this process, three studies were excluded, and finally only one study met the criteria for inclusion in this review.
Discussion and conclusion: A single study was found to show data on efficacy, safety, and tolerability in patients with medium-term treatments. Since the evidence identified contains significant biases, it is not possible to establish a recommendation favoring the prescription of one of the antipsychotics in the study over the other.
References
Bazrafshan, A., Zare, M., Bazrafshan, M., Zare, F., & Mazhari, S. (2017). Brexpiprazole versus placebo for people with schizophrenia. Cochrane Database of Systematic Reviews 3, CD012580. https://doi.org/10.1002/14651858.cd012580
Belgamwar, R. B., & El-Sayeh, H. G. G. (2011). Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, 8 ,CD006622. https://doi.org/10.1002/14651858.cd006622.pub2
Bhattacharjee, J., & El-Sayeh, H. G. (2008). Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews, 3, CD006617. https://doi.org/10.1002/14651858.cd006617.pub3
Brown, R., Taylor, M. J., & Geddes, J. (2013). Aripiprazole alone or in combination for acute mania. Cochrane Database of Systematic Reviews, 12, CD005000. https://doi.org/10.1002/14651858.cd005000.pub2
Citrome, L. (2015). The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. International Journal of Clinical Practice, 69(11), 1211-1220. https://doi.org/10.1111/ijcp.12752
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016a). The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia. International Clinical Psychopharmacology, 31(4), 192-201. https://doi.org/10.1097/yic.0000000000000123
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E. & Baker, R. (2016b). Treatment of acute schizophrenia in adult patients using either brexpiprazole (OPC-34712) or aripiprazole, an exploratory study. CNS Spectrums, 21(1), 77-121. https://doi.org/10.1017/S1092852915000905
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E. & Baker, R. (2015b). The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: An exploratory study. Biological Psychiatry, 77(9). 203s.
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E, & Baker, R. (2015c). Brexpiprazole (OPC-34712) vs aripiprazole in adults with acute schizophrenia: A multicenter, randomized, open-label, flexible-dose, exploratory study. European Neuropsychopharmacology, (2), S516-S517. https://doi.org/10.1097/YIC.0000000000000123
Correll, C. U., & Schooler, N. R. (2020). Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatric Disease and Treatment,16, 519-534. https://doi.org/10.2147/ndt.s225643
El-Sayeh, H. G., & Morganti, C. (2006). Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews, 2, CD004578. https://doi.org/10.1002/14651858.cd004578.pub3
Frankel, J. S., & Schwartz, T. L. (2017). Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therapeutic Advances in Psychopharmacology, 7(1), 29-41. https://doi.org/10.1177/2045125316672136
GRADEpro, G. D. T. (2015). Computer program. McMaster University (developed by Evidence Prime).
Hasan, A., Falkai, P., Lehmann, I., & Gaebel, W. (2020). Schizophrenia. Deutsches Ärzteblatt International. https://doi.org/10.3238/arztebl.2020.0412
Hey, S. P., & Kimmelman, J. (2014). The questionable use of unequal allocation in confirmatory trials. Neurology, 82(1), 77-79. https://doi.org/10.1212/01.wnl.0000438226.10353.1c
Higgins, J. P., Savović, J., Page, M. J., Elbers, R. G. & Sterne, J. A. (2023). Assessing risk of bias in a randomized trial. In: J. P. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, V. A. Welch (Eds). Cochrane Handbook for Systematic Reviews of Interventions (p.p. 205-228). https://doi.org/10.1002/9781119536604.ch8
Hirsch, L. E., & Pringsheim, T. (2016). Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, 6, CD009043. https://doi.org/10.1002/14651858.cd009043.pub3
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet, 394(10202), 939-951. https://doi.org/10.1016/s0140-6736(19)31135-3
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014). Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews, 10, CD006569. https://doi.org/10.1002/14651858.cd006569.pub5
Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2021). Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacology Reports, 41(2), 134-143. https://doi.org/10.1002/npr2.12180
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., & Iwata, N. (2020). Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology, 237(5), 1459-1470. https://doi.org/10.1007/s00213-020-05472-5
Martínez-Vélez, N. A., Escamilla Orozco, R. I., Flores Medina, Y., Saracco-Alvarez, R. A., Rosel Vales, M., Aguilar-Salas, I., & Sánchez-Hernández, G. Y. (2023). Aripiprazole versus brexpiprazole for people with schizophrenia. Cochrane Database of Systematic Reviews, 2, CD014670. https://doi.org/10.1002/14651858.cd014670
McCutcheon, R. A., Reis Marques, T., & Howes, O. D. (2020). Schizophrenia—An Overview. JAMA Psychiatry, 77(2), 201. https://doi.org/10.1001/jamapsychiatry.2019.3360
Mihaljević-Peleš, A., Bajs Janović, M., Šagud, M., Živković, M., Janović, Š. & Jevtović, S. (2019). Cognitive deficit in schizophrenia: an overview. Psychiatria Danubina, 31 Suppl 2, 139-142.
Millier, A., Schmidt, U., Angermeyer, M., Chauhan, D., Murthy, V., Toumi, M., & Cadi-Soussi, N. (2014). Humanistic burden in schizophrenia: A literature review. Journal of Psychiatric Research, 54, 85-93. https://doi.org/10.1016/j.jpsychires.2014.03.021
Ostinelli, E. G., Jajawi, S., Spyridi, S., Sayal, K., & Jayaram, M. B. (2018). Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews, 1, CD008074. https://doi.org/10.1002/14651858.cd008074.pub2
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. The Lancet, 388(10039), 86-97. https://doi.org/10.1016/s0140-6736(15)01121-6
Ralovska, S., Koychev, I., Marinov, P., Furukawa, T. A., Mulsant, B., & Cipriani, A. (2023). Brexpiprazole versus placebo or other antidepressive agents for treating depression. Cochrane Database of Systematic Reviews, 7, CD013866. https://doi.org/10.1002/14651858.cd013866.pub2
Review Manager Web (2023). Version 6.1.0. The Cochrane Collaboration. https://revman.cochrane.org/
Schünemann, H. J., Higgins, J. P., Vist, G. E., Glasziou, P., Akl, E. A., Skoetz, N., Guyatt, G.H. & Cochrane GRADEing Methods Group (formerly Applicability and Recommendations Methods Group) and the Cochrane Statistical Methods Group. (2023). Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: J. P. Higgins, J. Thoma, J. Chandler, M. Cumpston, T. Li, M. J. Page, V. A. Welch, (Eds.), Cochrane Handbook for Systematic Reviews of Interventions (p.p. 375-402). https://doi.org/10.1002/9781119536604.ch14
Sommer, I. E., Tiihonen, J., van Mourik, A., Tanskanen, A., & Taipale, H. (2020). The clinical course of schizophrenia in women and men—a nation-wide cohort study. npj Schizophrenia, 6(1). https://doi.org/10.1038/s41537-020-0102-z
Stahl, S. M. (2016). Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectrums, 21(1), 1-6. https://doi.org/10.1017/s1092852915000954
Ward, K., & Citrome, L. (2019). Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment, 15, 247-257. https://doi.org/10.2147/ndt.s169369
